Rx License-Rx

TAB-2417

Sirt1 LoxP (Sirt1tm1Cxd) Mouse Model for Metabolism and Hepatology Studies

Generation of floxed Sirtuin 1 Exon5-Exon6 for the construction of conditional knockout mice. Sirtuin 1 (Sirt1), a homolog of yeast Sir 2, is an NAD-dependent histone and protein deacetylase. It has a wide range of biological functions, ranging from DNA damage repair to effects on glucose metabolism. Sirt1 null mice die before birth due to chromosomal aberrations and impaired DNA damage repair. Sirt1 is thought to affect energy metabolism, but the mechanism remains poorly understood. In order to study tissue-specific metabolic effects of Sirt1, floxed Sirt1 was constructed so that exons 5 and 6 would be deleted using the Cre-Lox strategy. In contrast to a previously reported deletion of Sirt1 exon4, no truncated (and potentially active) Sirt1 forms were detected when exons 5 and 6 were deleted. Hepatic exon 5-6 null Sirt1 mice were generated when Floxed Sirt1 exon 5 and 6 mice were mated with mice that expressed the Cre-recombinase in...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Cardiometabolic

Indication: Liver disease

Modality: Biologic

Focus tags: Cardiometabolic

Technology tags: Biologic, Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: Research Material

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Cardiometabolic. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Liver disease. Public description: Generation of floxed Sirtuin 1 Exon5-Exon6 for the construction of conditional knockout mice. Sirtuin 1 (Sirt1), a homolog of yeast Sir 2, is an NAD-dependent histone and protein deacetylase. It has a wide range of biological functions.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Roche Diagnostics — Companion diagnostic and translational biomarker fit. Thermo Fisher — Research-tool commercialization and pharma services channels. Illumina / Tempus — Data, sequencing, and clinical decision-support adjacency.

Development Strategy to Increase PoS

First indication: Liver disease

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Best next experiment: Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.